Jubilant Pharmova has postponed its board meeting scheduled to consider the first quarter of FY26 financial results. The company announced on August 5, 2026, that the meeting originally set for Friday, August 7, 2026, has been rescheduled to Monday, August 10, 2026, due to unavoidable circumstances. This delay means investors will receive the Q1FY26 standalone and consolidated financial statements later than initially planned.

The postponement is governed by the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board of Directors will use the rescheduled session to approve the unaudited financial results for the quarter ended June 30, 2026. No specific reason beyond "unavoidable circumstances" was provided in the intimation filed with BSE Limited and the National Stock Exchange of India Limited.

Trading Window Status

The trading window for dealing in the securities of Jubilant Pharmova remains closed for designated persons and their immediate relatives. This restriction, which began on Wednesday, July 01, 2026, will continue until Wednesday, August 12, 2026, inclusive. The closure aligns with the company's Code of Conduct framed pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended. Designated persons have been informed of the extended closure period.

Key Dates

The company secretary, Naresh Kapoor, signed the intimation on August 5, 2026. The notice was issued from the company's registered office in Noida, Uttar Pradesh. As a Jubilant Bhartia Company, Jubilant Pharmova continues to adhere to regulatory disclosure norms despite the scheduling change.

Jubilant Pharmova Limited has recommended a final dividend of ₹5 per equity share for the financial year ended March 31, 2026, subject to shareholder approval at its 48th Annual General Meeting (AGM) scheduled for Wednesday, August 26, 2026. The meeting will be held via Video Conferencing (VC) or Other Audio-Visual Means (OAVM), allowing members to participate without physical presence. This dividend recommendation follows a strong FY26 performance where revenue grew 14% year-over-year to ₹82,796 Million, driven by robust demand in the CDMO Sterile Injectables segment.

The Board of Directors has fixed Friday, July 24, 2026, as the record date for determining dividend entitlements. Shareholders whose names appear in the Register of Members on this date will be eligible to receive the dividend, which aggregates to ₹796.41 Million. The dividend is taxable in the hands of shareholders pursuant to the Finance Act, 2020, effective April 1, 2020. To facilitate Tax Deducted at Source (TDS) compliance under the Income-tax Act, 1961, shareholders are required to submit relevant tax documents to investors@jubl.com on or before Friday, August 14, 2026. Failure to update bank details with Depository Participants or the Registrar and Transfer Agent, Alankit Assignments Limited, may delay dividend payments.

E-Voting Schedule and Procedures

Shareholders can cast their votes electronically through the National Securities Depository Limited (NSDL) platform. The e-voting process adheres to Section 108 of the Companies Act, 2013, Rule 20 of the Companies (Management and Administration) Rules, 2014, and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The cut-off date for determining voting rights is Wednesday, August 19, 2026. Only members holding shares as of this date will be eligible to vote.

The following table outlines the critical dates for the AGM and e-voting process:

Members who have already voted via remote e-voting can attend the AGM but cannot vote again. Those who have not voted remotely can exercise their voting rights during the meeting via VC/OAVM. Once a vote is cast, it cannot be modified. Shareholders without registered email addresses should update their details using Form ISR-1 with Alankit Assignments Limited or their respective Depository Participants.

FY26 Financial Highlights

The dividend recommendation is supported by solid operational growth in FY26. Total revenue from operations rose to ₹82,796 Million from ₹72,345 Million in FY25. The CDMO Sterile Injectables segment was a key driver, with revenue surging 38% to ₹17,548 Million, aided by commercial technology transfers from the Spokane facility’s Line 3. Radiopharma revenue also grew 9% to ₹36,901 Million.

While reported Profit After Tax (PAT) declined to ₹3,975 Million from ₹8,363 Million due to exceptional items, Normalised PAT increased 7% to ₹4,424 Million, reflecting improved core operating performance. EBITDA stood at ₹13,255 Million with a margin of 16%, compared to 17% in the previous year. The company continues to track towards its Vision 2030 targets, including doubling revenues from the FY24 baseline and achieving zero net debt.

Director Re-appointments

The AGM will also consider the re-appointment of two directors retiring by rotation: Mr. Hari Shanker Bhartia, Co-Chairman, and Mr. Arjun Shanker Bhartia, Joint Managing Director. Both directors attended all six Board meetings held during FY26. Mr. Hari Shanker Bhartia, a Chemical Engineering graduate from IIT Delhi, has served on the Board since November 1, 1983. Mr. Arjun Shanker Bhartia, who joined the Board in May 2017, has been Joint Managing Director since June 2023.